Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladder
Zhong, Hui (Rancho Los Amigos National Rehabilitation Center)
Liu, Emilie (SpineX (Estats Units d'Amèrica))
Kohli, Priya (Keck School of Medicine of University of Southern California)
Perez, Laura (Keck School of Medicine of University of Southern California)
Edgerton, Victor (Institut Germans Trias i Pujol. Institut Guttmann)
Ginsberg, David (Keck School of Medicine of University of Southern California)
Gad, Parag (SpineX (Estats Units d'Amèrica))
Kreydin, Evgeniy (Keck School of Medicine of University of Southern California)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Overactive bladder (OAB) affects 12 to 30% of the world's population. The accompanying urinary urgency, frequency and incontinence can have a profound effect on quality of life, leading to depression, social isolation, avoidance of sexual activity and loss of productivity. Conservative measures such as lifestyle modification and pelvic floor physical therapy are the first line of treatment for overactive bladder. Patients who fail these may go on to take medications, undergo neuromodulation or receive injection of botulinum toxin into the bladder wall. While effective, medications have side effects and suffer from poor adherence. Neuromodulation and botulinum toxin injection are also effective but are invasive and not acceptable to some patients. We have developed a novel transcutaneous spinal cord neuromodulator (SCONE™,) that delivers multifrequency electrical stimulation to the spinal cord without the need for insertion or implantation of stimulating electrodes. Previously, multifrequency transcutaneous stimulation has been demonstrated to penetrate to the spinal cord and lead to motor activation of detrusor and external urethral sphincter muscles. Here, we report on eight patients with idiopathic overactive bladder, who underwent 12 weeks of SCONE™ therapy. All patients reported statistically significant clinical improvement in multiple symptoms of overactive bladder, such as urinary urgency, frequency and urge incontinence. In addition, patients reported significant symptomatic improvements as captured by validated clinical surveys. SCONE™ therapy represents the first of its kind therapy to treat symptoms of urgency, frequency and urge urinary incontinence in patients with OAB. The study was listed on clinicaltrials. gov ().
Nota:	Altres ajuts: Academy of Finland 129164
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Non-invasive spinal cord stimulation ; Urge urinary incontinence ; Overactive bladder ; Lower urinary tract ; Urodynamics
Publicat a:	Bioelectronic Medicine, Vol. 8 (march 2022) , ISSN 2332-8886

DOI: 10.1186/s42234-022-00087-x
PMID: 35317851

9 p, 1.8 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats